MH3D Inc. Announces Sale of Alpha-SPECT™ Mini Unit to Perceptive Discovery Supporting Launch of α-Sight™ Alpha Imaging Service

Ann Arbor, MI — April 15th, 2026— MH3D Inc., a developer of next-generation quantitative SPECT imaging systems, today announced the sale of a Alpha-SPECT™ Mini unit to Perceptive Discovery, a leading contract research organization (CRO). The system will be used to support the launch of α-Sight™, a new pre-clinical imaging service focused on alpha-emitting radiopharmaceuticals.

This transaction marks a key commercial milestone for MH3D and reflects increasing demand for imaging technologies capable of directly visualizing and quantifying alpha-emitting therapies.

MH3D's Alpha-SPECT™ Mini is a CZT-based SPECT imaging platform purpose-built to address a longstanding limitation in the field: the inability to directly image alpha-emitting isotopes without relying on surrogate signals. The system enables high-sensitivity, multi-energy imaging and supports absolute quantification across complex decay chains.

The α-Sight™ service leverages these capabilities to provide direct, in vivo imaging of alpha-emitting isotopes, longitudinal same-animal studies, and multi-timepoint biodistribution analysis, enabling more accurate assessment of drug distribution, safety, and efficacy.

In addition to the sale of the Alpha-SPECT™ Mini, MH3D and Perceptive Discovery have entered into a partnership to leverage Perceptive’s extensive experience with radiochemistry, imaging and image analysis to expand and enhance the portfolio of isotopes and decision-making outputs in a broad array of use cases.

“This represents an important step in bringing quantitative alpha imaging into routine pre-clinical workflows,” said Xiaopei Huang, CEO and Founder of MH3D. “There is a clear need for technologies that can provide accurate, transparent data for alpha-emitting therapies, and we are encouraged to see adoption within the CRO community.”

“The capabilities of the Alpha-SPECT™ Mini enable new types of studies and data insights that were previously difficult or impossible to achieve,” said Ben Murphy, CEO of Perceptive Discovery. “This allows for more direct evaluation of radiopharmaceutical behavior in vivo, and better results for our partners.”

At the core of the Alpha-SPECT™ Mini system are several key technical advantages, including:

• High quantification accuracy (~1–10% error across multiple energy peaks)

• CZT-based detector technology with ~2.5% energy resolution at 140 keV

• Multi-isotope imaging for complex decay chains such as Actinium-225

• Dynamic and longitudinal imaging with minute-level temporal resolution

• Reduced scan times and lower dose requirements for alpha-emitting isotopes

  
  

These capabilities support a range of applications including biodistribution studies, dosimetry modeling, pharmacokinetics, and IND-enabling research.

The deployment of the Alpha-SPECT™ Mini in a CRO setting highlights a broader industry shift toward quantitative, reproducible imaging as radiopharmaceutical pipelines expand and demand higher-quality data to support development and regulatory decisions.

About MH3D, Inc.

 MH3D Inc. is a medical imaging company developing next generation quantitative SPECT systems, powered by CZT detectors and advanced nuclear medicine imaging software. The company focuses on Alpha-SPECT™ platform enabling absolute quantification for theranostics across pre-clinical and future clinical applications.

Learn more about MH3D, Inc. at https://www.mh3dinc.com/

About Perceptive Discovery

Perceptive Discovery is a scientific partner to the global biopharmaceutical industry, providing integrated preclinical solutions across oncology, CNS, and radiopharmaceutical development. The company combines expertise in imaging, radiochemistry, and quantitative analysis to deliver high-quality, decision-ready data from early discovery through IND-enabling studies.

Learn more about Perceptive Discovery at https://www.perceptive.com/about-perceptive-discovery/